Advertisement

CD26/DP IV in T Cell Activation and Autoimmunity

  • Vera Preller
  • Annegret Gerber
  • Mauro Togni
  • Sabine Wrenger
  • Burkhart Schraven
  • Christoph Röcken
  • Didier Marguet
  • Siegfried Ansorge
  • Stefan Brocke
  • Dirk Reinhold
Part of the Advances in Experimental Medicine and Biology book series (volume 575)

4. Conclusions

In summary, the present study demonstrates a critical role for CD26/DP IV in balancing Th1 immune responses. We observed a deregulation of the autoimmune process in EAE in vitro, the prototypic model of an immune-mediated CNS disorder. Our results support the notion of a critical regulatory role for the CD26/DP IV molecule within the immune system.

Keywords

Multiple Sclerosis Experimental Autoimmune Encephalomyelitis Myelin Basic Protein Optic Neuritis Dipeptidyl Peptidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ansorge S, Schön E, and Kunz D, 1991, Membrane-bound peptidases of lymphocytes: Functional implications. Biomed Biochem Acta. 50: 799–807.Google Scholar
  2. Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, and Trent JM, 2003, Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet. 12: 2191–2199.CrossRefPubMedGoogle Scholar
  3. Constantinescu CS, Kamoun M, Dotti M, Farber RE, Galetta SL, and Rostami A, 1995, A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. J Neurol Sci. 130: 178–182.CrossRefPubMedGoogle Scholar
  4. Dang NH, Torimoto Y, Deusch K, Schlossman SF, and Morimoto C, 1990, Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol. 144: 4092–4100.PubMedGoogle Scholar
  5. De Meester I, Korom S, Van Damme J, and Scharpe’ S, 1999, CD26, let it cut or cut it down. Immunol Today. 20: 367–375.CrossRefPubMedGoogle Scholar
  6. Fleischer B, 1994, CD26: a surface protease involved in T-cell activation. Immunol Today. 15: 180–184.CrossRefPubMedGoogle Scholar
  7. Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, and Weiner HL, 1985, In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 312: 1405–1411.PubMedCrossRefGoogle Scholar
  8. Hopsu-Havu KV, and Glenner GG, 1966, A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-betanaphthylamide. Histochemie. 7: 197–201.CrossRefPubMedGoogle Scholar
  9. Jensen J, Langkilde AR, Fenst C, Nicolaisen MS, Roed HG, Christiansen M, and Sellebjerg F, 2004, CD4 T cell activation and disease activity at onset of multiple sclerosis. J Neuroimmunol. 149: 202–209.CrossRefPubMedGoogle Scholar
  10. Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, and Reinhold D, 1999, Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth. Int J Mol Med. 4: 3–15.PubMedGoogle Scholar
  11. Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, and Weiner HL, 2000, Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol. 57: 1183–1189.CrossRefPubMedGoogle Scholar
  12. Lojda Z, 1977, Studies on glycyl-proline naphthylamidase. I. Lymphocytes. Histochemistry. 54: 299–309.CrossRefPubMedGoogle Scholar
  13. Marguet D, Baggio, L, Kobayashi, T, Bernard, AM, Pierres, M, Nielsen, PF, Ribel, U, Watanabe, T, Drucker, DJ, Wagtmann, N, 2000, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA. 97: 6874–6879.CrossRefPubMedGoogle Scholar
  14. Reinhold D, Bank U, Bühling F, Lendeckel U, Faust J, Neubert K, and Ansorge S, 1997, Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-β1 in PWM-stimulated PBMC and T cells. Immunology. 91: 354–360.CrossRefPubMedGoogle Scholar
  15. Reinhold D, Hemmer B, Gran B, Born I, Faust J, Neubert K, McFarland HF, Martin R, and Ansorge S, 1998, Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. J Neuroimmunol. 87: 203–209.CrossRefPubMedGoogle Scholar
  16. Schön E, Mansfeld HW, Demuth HU, Barth A, and Ansorge S, 1985. The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochem Acta. 44: K9–K15.Google Scholar
  17. Sedo A, Malik R, 2001, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Bioch Biophys Acta. 1550: 107–116.Google Scholar
  18. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, and Garred P, 2000a, CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol. 102: 98–106.CrossRefPubMedGoogle Scholar
  19. Sellebjerg F, Christiansen M, Jensen J, and Frederiksen JL, 2000b, Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol. 7: 281–289.CrossRefPubMedGoogle Scholar
  20. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, and Brocke S, 2000, Dipeptidyl peptidase IV in inflammatory CNS disease. Adv Exp Med Biol. 477: 145–153.PubMedCrossRefGoogle Scholar
  21. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, and Brocke S, 2001, Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and upregulates TGF-β1 secretion in vivo. J Immunol. 166: 2041–2048.PubMedGoogle Scholar
  22. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, and Morimoto C, 1991, Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol. 147: 2514–2517.PubMedGoogle Scholar
  23. Wrenger S, Hoffmann T, Faust J, Mrestani-Klaus C, Brandt W, Neubert K, Kraft M, Olek S, Frank R, Ansorge S, and Reinhold D, 1997, The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. J Biol Chem. 272: 30283–30288.CrossRefPubMedGoogle Scholar
  24. Wrenger S, Faust J, Mrestani-Klaus C, Fengler A, Stöckel-Maschek A, Lorey S, Kähne T, Brandt W, Neubert K, Ansorge S, and Reinhold D, 2000, Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor. J Biol Chem. 275: 22180–22186.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Vera Preller
    • 5
  • Annegret Gerber
    • 5
  • Mauro Togni
    • 5
  • Sabine Wrenger
    • 5
  • Burkhart Schraven
    • 5
  • Christoph Röcken
    • 1
  • Didier Marguet
    • 2
  • Siegfried Ansorge
    • 3
  • Stefan Brocke
    • 4
  • Dirk Reinhold
    • 5
  1. 1.Institute of PathologyOtto-von-Guericke UniversityMagdeburgGermany
  2. 2.Centre d’Immunologie de Marseille LuminyFrance
  3. 3.Institute of Medical Technology Magdeburg, IMTMMagdeburgGermany
  4. 4.Department of PathologyHebrew University, Hadassah Medical SchoolJerusalemIsrael
  5. 5.Institute of ImmunologyOtto-von-Guericke UniversityMagdeburgGermany

Personalised recommendations